Lacosamid Stada (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyper‑excitable neurons, limits repetitive firing, and thereby diminishes the likelihood of seizure propagation.

The exact dose is determined by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. Typical dosing starts low and is gradually increased to achieve optimal seizure control while monitoring tolerability.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow inactivation of sodium channels—differs from agents like carbamazepine that target fast inactivation. It is generally well tolerated and may be preferred for patients who experience side effects with other sodium‑channel blockers, though individual response varies.

Lacosamid Stada should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture. Keep the product out of direct sunlight and out of reach of children.

Lacosamide is taken orally, usually as tablets or oral solution. The medication should be swallowed whole with water and taken at the same times each day to maintain consistent blood levels.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, hypersensitivity reactions, and rare cases of hepatic injury. Prompt medical attention is required if any of these occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug, those with severe cardiac conduction disorders (e.g., second‑ or third‑degree AV block without a pacemaker), and individuals for whom the risk of seizure worsening outweighs potential benefits. A healthcare professional should evaluate suitability before prescribing.